Protalix BioTherapeutics, Inc. (PLX)
| Market Cap | 159.53M -33.4% |
| Revenue (ttm) | 76.38M +27.8% |
| Net Income | 15.33M +292.3% |
| EPS | 0.19 +323.9% |
| Shares Out | 80.57M |
| PE Ratio | 10.25 |
| Forward PE | 7.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,100,822 |
| Open | 2.000 |
| Previous Close | 2.000 |
| Day's Range | 1.950 - 2.045 |
| 52-Week Range | 1.320 - 3.190 |
| Beta | -0.01 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+506.06%) |
| Earnings Date | May 13, 2026 |
About PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for PLX stock is "Strong Buy" and the 12-month stock price target is $12.0.
News
Protalix BioTherapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw a $25M milestone from Chiesi, driving net income to $18.2M and cash to $51M. Revenue guidance for 2026 is reaffirmed at $78–$83M, with strong momentum for Elfabrio and ongoing PRX-115 clinical progress.
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; $25...
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, May 6, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on th...
Protalix BioTherapeutics Earnings Call Transcript: Q4 2025
EU approval of Elfabrio's four-week dosing triggered a $25M milestone, boosting projected 2026 cash to $50M and supporting revenue growth over 50%. Pipeline advances in gout and renal indications, with strong commercial execution and high-margin contributions from Chiesi.
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry disease...
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, March 11, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on...
Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio
Chiesi Global Rare Diseases and Protalix (PLX) BioTherapeutics announced that the European Commission has approved the 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults living with Fabry dise...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approve...
Protalix, Chiesi Global: CHMP issues positive opinion for Elfabrio dosing
Chiesi Global Rare Diseases and Protalix (PLX) BioTherapeutics announced an update on Elfabrio. The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positiv...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2...
Protalix BioTherapeutics Letter to Stockholders
CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization o...
Protalix, Secarna Pharmaceuticals enter collaboration and option agreement
Protalix (PLX) and Secarna Pharmaceuticals announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of no...
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications Protalix i...
Protalix price target lowered to $12 from $15 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Protalix (PLX) to $12 from $15 and keeps a Buy rating on the shares following the Q3 report. The…
Protalix BioTherapeutics Earnings Call Transcript: Q3 2025
Nine-month revenues rose 24% year-over-year to $43.6 million, with Q3 net income of $2.4 million. PRX-115 phase II trial is set to begin soon, and cash reserves of $29.4 million are expected to fund operations for at least 12 months.
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EST CARMIEL, Israel , Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focu...
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
Company to host conference call and webcast at 8:00 a.m. EST CARMIEL, Israel , Nov. 6, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on ...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
-- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU -- -- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --
Protalix, Chiesi Global: CHMP issues negative opinion for Elfabrio
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix (PLX) BioTherapeutics ackn...
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
Every two weeks remains approved as a dosing regimen of Elfabrio in the EU Every two weeks remains approved as a dosing regimen of Elfabrio in the EU
Protalix BioTherapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025
The presentation highlighted a unique plant cell technology platform, two approved drugs, and a promising pipeline asset for gout. Key catalysts include an EMA decision on monthly Elfabrio dosing and the start of a pivotal phase II trial for PRX-115, with strong financial footing supporting ongoing operations.
Protalix BioTherapeutics to Present at Investor Summit Virtual
CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CARMIEL, Israel, Sept. 2, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombina...
Protalix BioTherapeutics Earnings Call Transcript: Q2 2025
Q2 2025 saw a 16% revenue increase and a return to profitability, driven by strong Elfabrio sales to Chiesi and reduced costs. R&D spending doubled in preparation for PRX-115 phase II, and the company expects Elfabrio royalties to exceed $100 million by 2030.